These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 26439694)

  • 21. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.
    Curiel-Olmo S; García-Castaño A; Vidal R; Pisonero H; Varela I; León-Castillo A; Trillo E; González-Vela C; García-Diaz N; Almaraz C; Moreno T; Cereceda L; Madureira R; Martinez N; Ortiz-Romero P; Valdizán E; Piris MA; Vaqué JP
    Oncotarget; 2015 Sep; 6(28):25452-65. PubMed ID: 26327537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
    Rizvi NA; Hellmann MD; Snyder A; Kvistborg P; Makarov V; Havel JJ; Lee W; Yuan J; Wong P; Ho TS; Miller ML; Rekhtman N; Moreira AL; Ibrahim F; Bruggeman C; Gasmi B; Zappasodi R; Maeda Y; Sander C; Garon EB; Merghoub T; Wolchok JD; Schumacher TN; Chan TA
    Science; 2015 Apr; 348(6230):124-8. PubMed ID: 25765070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study.
    Bai X; Wu DH; Ma SC; Wang J; Tang XR; Kang S; Fu QJ; Cao CH; Luo HS; Chen YH; Zhu HB; Yan HH; Wu YL; Dong ZY
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
    Kogure Y; Saka H; Oki M; Saito TI; Ahmed SN; Kitagawa C; Imaizumi K
    PLoS One; 2015; 10(8):e0135393. PubMed ID: 26262682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
    Damotte D; Warren S; Arrondeau J; Boudou-Rouquette P; Mansuet-Lupo A; Biton J; Ouakrim H; Alifano M; Gervais C; Bellesoeur A; Kramkimel N; Tlemsani C; Burroni B; Duche A; Letourneur F; Si H; Halpin R; Creasy T; Herbst R; Ren X; Morel P; Cesano A; Goldwasser F; Leroy K
    J Transl Med; 2019 Nov; 17(1):357. PubMed ID: 31684954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy.
    Masago K; Fujita S; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Sakamori Y; Mio T; Mishima M
    Clin Lung Cancer; 2011 Jan; 12(1):56-61. PubMed ID: 21273181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.
    Li SD; Ma M; Li H; Waluszko A; Sidorenko T; Schadt EE; Zhang DY; Chen R; Ye F
    Genome Med; 2017 Oct; 9(1):89. PubMed ID: 29082853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.
    Trefny MP; Rothschild SI; Uhlenbrock F; Rieder D; Kasenda B; Stanczak MA; Berner F; Kashyap AS; Kaiser M; Herzig P; Poechtrager S; Thommen DS; Geier F; Savic S; Jermann P; Alborelli I; Schaub S; Stenner F; Früh M; Trajanoski Z; Flatz L; Mertz KD; Zippelius A; Läubli H
    Clin Cancer Res; 2019 May; 25(10):3026-3034. PubMed ID: 30765392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
    Garofalo A; Sholl L; Reardon B; Taylor-Weiner A; Amin-Mansour A; Miao D; Liu D; Oliver N; MacConaill L; Ducar M; Rojas-Rudilla V; Giannakis M; Ghazani A; Gray S; Janne P; Garber J; Joffe S; Lindeman N; Wagle N; Garraway LA; Van Allen EM
    Genome Med; 2016 Jul; 8(1):79. PubMed ID: 27460824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
    Wang Z; Duan J; Wang G; Zhao J; Xu J; Han J; Zhao Z; Zhao J; Zhu B; Zhuo M; Sun J; Bai H; Wan R; Wang X; Fei K; Wang S; Zhao X; Zhang Y; Huang M; Huang D; Qi C; Gao C; Bai Y; Dong H; Xiong L; Tian Y; Wang D; Xu C; Wang W; Li J; Hu X; Cai S; Wang J
    J Thorac Oncol; 2020 Apr; 15(4):556-567. PubMed ID: 31843683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
    Fukihara J; Watanabe N; Taniguchi H; Kondoh Y; Kimura T; Kataoka K; Matsuda T; Yokoyama T; Hasegawa Y
    Oncology; 2014; 86(2):86-93. PubMed ID: 24457318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.
    Esposito Abate R; Pasquale R; Sacco A; Simeon V; Maiello MR; Frezzetti D; Chiodini P; Normanno N
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
    Li W; Ren S; Li J; Li A; Fan L; Li X; Zhao C; He Y; Gao G; Chen X; Li S; Shi J; Zhou C; Fei K; Schmid-Bindert G
    Lung Cancer; 2014 Jun; 84(3):295-300. PubMed ID: 24685306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
    Zhang W; Shi F; Kong Y; Li Y; Sheng C; Wang S; Wang Q
    Cancer Med; 2022 Feb; 11(3):676-691. PubMed ID: 34862763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
    Roszik J; Haydu LE; Hess KR; Oba J; Joon AY; Siroy AE; Karpinets TV; Stingo FC; Baladandayuthapani V; Tetzlaff MT; Wargo JA; Chen K; Forget MA; Haymaker CL; Chen JQ; Meric-Bernstam F; Eterovic AK; Shaw KR; Mills GB; Gershenwald JE; Radvanyi LG; Hwu P; Futreal PA; Gibbons DL; Lazar AJ; Bernatchez C; Davies MA; Woodman SE
    BMC Med; 2016 Oct; 14(1):168. PubMed ID: 27776519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy.
    Lu M; Wu KH; Trudeau S; Jiang M; Zhao J; Fan E
    Sci Rep; 2020 Nov; 10(1):20575. PubMed ID: 33239757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
    Roh W; Chen PL; Reuben A; Spencer CN; Prieto PA; Miller JP; Gopalakrishnan V; Wang F; Cooper ZA; Reddy SM; Gumbs C; Little L; Chang Q; Chen WS; Wani K; De Macedo MP; Chen E; Austin-Breneman JL; Jiang H; Roszik J; Tetzlaff MT; Davies MA; Gershenwald JE; Tawbi H; Lazar AJ; Hwu P; Hwu WJ; Diab A; Glitza IC; Patel SP; Woodman SE; Amaria RN; Prieto VG; Hu J; Sharma P; Allison JP; Chin L; Zhang J; Wargo JA; Futreal PA
    Sci Transl Med; 2017 Mar; 9(379):. PubMed ID: 28251903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
    Dempke WC; Sellmann L; Fenchel K; Edvardsen K
    Anticancer Res; 2015 Nov; 35(11):5745-57. PubMed ID: 26503995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
    Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
    Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.